Conduit Pharmaceuticals (CDT) Competitors $2.16 +0.06 (+2.86%) Closing price 07/22/2025 04:00 PM EasternExtended Trading$2.13 -0.03 (-1.16%) As of 07/22/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDT vs. INDP, AIM, GTBP, IXHL, CELZ, SBFM, SLXN, INAB, TCRT, and PPBTShould you be buying Conduit Pharmaceuticals stock or one of its competitors? The main competitors of Conduit Pharmaceuticals include Indaptus Therapeutics (INDP), AIM ImmunoTech (AIM), GT Biopharma (GTBP), Incannex Healthcare (IXHL), Creative Medical Technology (CELZ), Sunshine Biopharma (SBFM), Silexion Therapeutics (SLXN), IN8bio (INAB), Alaunos Therapeutics (TCRT), and Purple Biotech (PPBT). These companies are all part of the "pharmaceutical products" industry. Conduit Pharmaceuticals vs. Its Competitors Indaptus Therapeutics AIM ImmunoTech GT Biopharma Incannex Healthcare Creative Medical Technology Sunshine Biopharma Silexion Therapeutics IN8bio Alaunos Therapeutics Purple Biotech Conduit Pharmaceuticals (NASDAQ:CDT) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings. Is CDT or INDP more profitable? Conduit Pharmaceuticals' return on equity of 0.00% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Conduit PharmaceuticalsN/A N/A -435.57% Indaptus Therapeutics N/A -333.02%-216.36% Which has higher earnings and valuation, CDT or INDP? Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Conduit Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConduit PharmaceuticalsN/AN/A-$17.80M-$534.480.00Indaptus TherapeuticsN/AN/A-$15.02M-$41.74-0.26 Which has more risk & volatility, CDT or INDP? Conduit Pharmaceuticals has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Do analysts rate CDT or INDP? Indaptus Therapeutics has a consensus target price of $238.00, suggesting a potential upside of 2,099.63%. Given Indaptus Therapeutics' higher probable upside, analysts plainly believe Indaptus Therapeutics is more favorable than Conduit Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Conduit Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer CDT or INDP? In the previous week, Conduit Pharmaceuticals' average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score. Company Overall Sentiment Conduit Pharmaceuticals Neutral Indaptus Therapeutics Neutral Do insiders & institutionals hold more shares of CDT or INDP? 3.3% of Conduit Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 7.7% of Conduit Pharmaceuticals shares are held by company insiders. Comparatively, 20.8% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryIndaptus Therapeutics beats Conduit Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDT vs. The Competition Export to ExcelMetricConduit PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.68M$2.44B$5.48B$9.45BDividend YieldN/A1.80%4.01%4.03%P/E Ratio0.009.0628.3219.90Price / SalesN/A555.77409.9885.24Price / CashN/A165.2635.9658.29Price / Book-0.035.068.325.67Net Income-$17.80M$30.99M$3.24B$258.18M7 Day Performance-1.37%2.02%3.08%2.81%1 Month Performance-6.49%13.07%10.92%13.53%1 Year Performance-99.43%-1.92%34.24%17.68% Conduit Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTConduit Pharmaceuticals0.1326 of 5 stars$2.16+2.9%N/A-99.4%$1.68MN/A0.003INDPIndaptus Therapeutics3.033 of 5 stars$12.58+4.8%$238.00+1,791.9%-82.3%$7.20MN/A-0.306Positive NewsAIMAIM ImmunoTech1.3941 of 5 stars$9.17+0.9%$275.00+2,898.9%-77.3%$7.01M$146K-19.5120GTBPGT Biopharma1.4164 of 5 stars$2.14-4.0%$11.00+414.0%-26.6%$7.00MN/A-0.388Positive NewsIXHLIncannex Healthcare0.4215 of 5 stars$0.24+7.1%N/A-61.8%$6.95M$98K-0.203Gap DownHigh Trading VolumeCELZCreative Medical Technology1.0423 of 5 stars$2.64-9.3%N/A-23.9%$6.84M$10K-0.695Gap DownSBFMSunshine Biopharma2.6404 of 5 stars$1.49-3.2%$15.00+906.7%+417.1%$6.79M$36.23M-0.013Positive NewsSLXNSilexion TherapeuticsN/A$0.78-1.4%$5.00+541.8%N/A$6.77MN/A0.00N/APositive NewsINABIN8bio2.8766 of 5 stars$2.22-3.1%$180.00+8,008.1%-90.9%$6.72MN/A-0.1620TCRTAlaunos Therapeutics0.5614 of 5 stars$4.00-19.8%N/A-26.7%$6.56M$11K-1.5740Positive NewsGap UpHigh Trading VolumePPBTPurple Biotech2.0425 of 5 stars$2.53+5.4%$33.00+1,204.3%N/A$6.55MN/A-0.9720 Related Companies and Tools Related Companies Indaptus Therapeutics Alternatives AIM ImmunoTech Alternatives GT Biopharma Alternatives Incannex Healthcare Alternatives Creative Medical Technology Alternatives Sunshine Biopharma Alternatives Silexion Therapeutics Alternatives IN8bio Alternatives Alaunos Therapeutics Alternatives Purple Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDT) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDT Stock Alerts